Effect of anti-tumor necrosis factor on work disability

Journal of Rheumatology

Volumn 34, Issue 11, 2007, Pages 2126-2128

  Verstappen, Suzanne M M ^a   Jacobs, Johannes W G ^b   Hyrich, Kimme L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

DISEASE ACTIVITY; DISEASE CONTROL; EDITORIAL; EMPLOYMENT; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SELF REPORT; WORK DISABILITY;

ARTHRITIS, RHEUMATOID; HUMANS; TUMOR NECROSIS FACTOR-ALPHA; WORK CAPACITY EVALUATION;

EID: 35948982233     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (14)

1. Verstappen SM, Bijlsma JW, Verkleij H, et al. Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys. Arthritis Rheum 2004;51:488-97.
2. Yelin E. Work disability in rheumatic diseases. Curr Opin Rheumatol 2007;19:91-6.
3. Wolfe F, Michaud K, Choi HK, Williams R. Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol 2005;32:1875-83.
4. Verstappen SM, Boonen A, Verkleij H, Bijlsma JW, Buskens E, Jacobs JW. Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity. Ann Rheum Dis 2005;64:1754-60.
5. Kavanaugh A. Economic issues with new rheumatologic therapeutics. Curr Opin Rheumatol 2007;19:272-6.
6. Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34:2211-7.
7. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. Arthritis Rheum 2003;48:3046-54.
8. Smolen JS, Han C, van der Heijde D, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum 2006;54:716-22.
9. Laas K, Peltomaa R, Kautiainen H, Puolakka K, Leirisalo-Repo M. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis 2006;65:924-8.
10. Hyrich KL, Symmons DP, Watson KD, Silman AJ. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:1786-94.
11. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl 2:ii30-ii33.
12. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
13. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2007;56:2129-34.
14. Verstappen SM, Boonen A, Bijlsma JW, et al. Working status among Dutch patients with rheumatoid arthritis: work disability and working conditions. Rheumatology Oxford 2005;44:202-6.